UCSF Center for HIV Information

Susa Coffey, MD

Co-Investigator, Medical Editor

Website Manager

Web Developer

Producer

Production Manager

Resources: 5

Title	Publish Date Sort ascending	Review Date
Best Practices for Finding and Crediting Images	03/13/2023
Stock Image Website and Resource List	03/13/2023
HHS Adult ART Guidelines: Treatment-Experienced Patients	06/10/2021
HHS Adult ART Guidelines: Initial Therapy	06/10/2021
HHS Adult ART Guidelines: HIV and ART in Older People	01/31/2020

Articles: 49

Title	Publish date	Review date
Accessibility: The Bigger Picture	06/02/2016
TargetHIV: New Name, New Look	09/12/2018
Tissue Levels of TAF: Too Low for PrEP?	03/17/2016
Switching from TDF/FTC to TAF/FTC	03/18/2016
PrEP: Bone Density Improves after Stopping TDF/FTC	05/04/2016
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA	09/27/2016
HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052	09/27/2016
HIV Meds Update - RAPID: Immediate ART Initiation	09/27/2016
HIV Meds Update: PrEP Uptake by Sex, Race, and Age	09/27/2016
CROI 2017: Failure of Dolutegravir Monotherapy	04/17/2017
CROI 2017: Dolutegravir in 2-Drug Simplification Studies	04/17/2017
CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison	04/17/2017
CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment	04/17/2017
Bictegravir in Initial Therapy	09/28/2017
Doravirine in Initial Therapy: DRIVE-AHEAD Study	10/03/2017
Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission	12/19/2017
Ibalizumab Approved for Persons with Multidrug Resistant HIV	04/11/2018
Naltrexone Improves Virologic Suppression	04/11/2018
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study	04/11/2018
Immediate ART Initiation Improves Time to Viral Suppression	04/11/2018
Bictegravir/TAF/FTC in Women	04/11/2018
Bictegravir Approved for Initial ART, in Combination with TAF/FTC	04/11/2018
Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects	05/23/2018
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study	08/20/2018
Dolutegravir + 3TC in Initial Therapy	08/21/2018
U=U in PARTNER2 Study of MSM	08/21/2018
Doravirine--New NNRTI Approved by FDA	10/10/2018
Rapid ART Start	10/16/2018
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine	04/19/2019
PrEP: TDF/FTC vs TAF/FTC in MSM	04/25/2019
Long-Acting Injectable ART: Cabotegravir + Rilpivirine	04/25/2019
Safety of Dolutegravir at Conception: Updated Data	08/29/2020
New ARV Approval - Fostemsavir	09/04/2020
Long-acting Injectable PrEP: Cabotegravir	09/20/2020
HIV Meds Updates - TANGO and SALSA Studies: Switch to DTG/3TC from 3-Drug ART	10/18/2021	10/18/2021
HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine	10/18/2021	10/18/2021
HIV Meds Updates: Long-acting Injectable Therapy: Lenacapavir	10/18/2021	10/18/2021
Long-acting Injectable PrEP Approved: Cabotegravir	02/09/2022
Updated CDC PrEP Guidelines	02/09/2022
HIV Meds Update: Anal Dysplasia Treatment Prevents Anal Cancer - The ANCHOR Study	02/20/2023
FDA Approves Lenacapavir, New Long-Acting Injectable ARV	03/24/2023
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV	10/01/2015
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy	04/12/2016
Use of Dolutegravir in Dialysis	05/04/2016
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen	09/28/2017
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)	04/11/2018
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women	09/25/2018
Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy	09/25/2018
Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects	09/25/2018

UCSF CHI Online

Resources: 5

Articles: 49